<DOC>
	<DOCNO>NCT02053753</DOCNO>
	<brief_summary>Approximately 140 male female healthy subject randomize ( 1:1 ratio ) receive 120 mg single dose denosumab either 1.7 mL single injection 70 mg/mL denosumab CP4 ( Treatment A ) 1.7 mL single injection 70 mg/mL denosumab CP2 ( Treatment B ) . Subjects admit research facility day -1 remain research facility day 2 . The subject return research facility outpatient basis . The PK , PD , safety assessment conduct inpatient stay regular interval 18-week treatment period .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Single-Dose , Parallel-Group Study Healthy Volunteers Assess Bioequivalence 120 mg Denosumab Subcutaneous Dose When Administered Denosumab CP4 Drug Product Commercially Available Denosumab CP2 Drug Product</brief_title>
	<detailed_description />
	<mesh_term>Denosumab</mesh_term>
	<criteria>Key Inclusion : Healthy male female , age ≥ 18 ≤ 65 year ( inclusive ) Body weight &gt; 60 &lt; 100 kg time screen Clinically acceptable physical exam laboratory test ( blood hematology , blood chemistry , urinalysis ) history evidence clinically significant medical disorder would pose risk subject safety interfere study evaluation procedure Normal clinically acceptable electrocardiogram ( ECG ) ( 12lead report heart rate PR , QRS , QT , QTc interval ) screen Willing confine research facility 2 consecutive night Subject available followup assessment Prior diagnosis bone disease , condition affect bone metabolism , limited : osteoporosis , osteogenesis imperfecta , hyperparathyroidism , hyperthyroidism , hypothyroidism , osteomalacia , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , current flareup osteoarthritis and/or gout , active malignancy , renal disease ( defined glomerular filtration rate [ GFR ] &lt; 45 mL/min ) , Paget 's disease bone , recent bone fracture ( within 6 month ) , malabsorption syndrome Presents psychiatric disorder , may prevent subject complete study interfere interpretation study result Significant change physical activity 6 month study drug administration constant level intense physical exercise Prior use nonAmgen approve medication within 4 week 5half life ( whichever time period longer ) study drug administration duration study . This include medication , limited : bisphosphonates , fluoride , hormone replacement therapy ( ie , estrogen ) selective estrogen receptor modulator , ralaxofene , calcitonin , strontium , parathyroid hormone derivative , supplemental vitamin D [ &gt; 1000 IU/day ] , glucocorticosteroids , anabolic steroid , calcitriol , diuretic , counter medication , herbal supplement Positive human immunodeficiency virus ( HIV ) screen know diagnosis acquire immune deficiency syndrome ( AIDS ) Positive hepatitis B surface antigen ( HepBsAg ) ( indicative chronic hepatitis B ) detectable hepatitis C virus ribonucleic acid ( RNA ) polymerase chain reaction ( PCR ) screening ( indicative active hepatitis C screen generally do hepatitis C antibody [ HepCAb ] , follow hepatitis C virus RNA PCR HepCAb positive ) Known sensitivity product administer study Prior denosumab administration Receiving receive investigational drug ( currently use investigational device ) within 30 day receive study drug , least 10 time respective elimination halflife ( whichever period longer ) duration study Women positive pregnancy test screen day1 Men woman reproductive potential unwilling practice highly effective method birth control study 5 month receive last dose study drug . Highly effective method birth control include sexual abstinence ( men , woman ) ; vasectomy ; condom spermicide ( men ) combination either barrier method , hormonal birth control intrauterine device ( woman ) Women lactating/breastfeeding plan breastfeed study 5 halflives receive dose study drug Women plan become pregnant study 5 month receive dose study drug Men partner pregnant plan become pregnant subject study 5 month receive last dose study drug Unwilling unable limit alcohol consumption throughout course study . Alcohol prohibit 24 hour prior screen , 24 hour prior checkin day 1 , throughout confinement . Alcohol also limit 2 drink per day outpatient period study completion day 127 ( EOS ) . A standard drink equivalent 12 ounce regular beer , 8 9 ounce malt liquor , 5 ounce wine , 1.5 ounce 80 proof distil spirit Positive urine screen alcohol and/or drug high potential abuse screen day 1 . Rescreening subject within 48 hour positive result permit Any condition might reduce chance obtain data require protocol might compromise ability give truly informed consent and/or comply study procedure Osteonecrosis jaw ( ONJ ) risk factor ONJ invasive dental procedure ( eg , tooth extraction , dental implant , oral surgery past 6 month ) , poor oral hygiene , periodontal , and/or preexist dental disease Recent tooth extraction ( within 6 month screen visit ) Evidence hypocalcemia screen Known vitamin D deficiency Known intolerance calcium vitamin D supplement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>denosumab , bioequivalence</keyword>
</DOC>